Dr. Rainer Hubmann | Biomedical and Healthcare Applications | Best Researcher Award

Doctorate at Red Cross | Austria

Mag. Dr. Rainer Hubmann embarked on his academic journey at the University of Vienna, earning his master’s degree in Biology/Genetics in 1996. During this time, he became an active member of the Cell Cycle Club under the leadership of Kim Nasmyth at the Research Institute of Molecular Pathology (IMP). His passion for molecular biology led him to pursue his Ph.D. at the Medical University of Vienna, where he focused on the regulation of CD23 in Chronic Lymphocytic Leukemia (CLL), completing it in 2002.

Professional Profiles

Scopus

Orcid

🎓Education and Academic Background

Dr. Rainer Hubmann’s distinguished academic journey began at the University of Vienna, where he earned a Master’s degree in Biology and Genetics (1987–1996). During this time, he joined the prestigious Cell Cycle Club, led by Kim Nasmyth, sharpening his focus on cell cycle research. He pursued his Ph.D. thesis (1997–2002) at the Medical University of Vienna (MUW), investigating the Regulation of CD23 in Chronic Lymphocytic Leukemia (CLL). His postdoctoral work from 2002 to 2011 extended into pioneering studies on NOTCH2 regulation and the characterization of CLL stem cells. In 2022, he assumed the role of Group Leader and Senior Scientist at the Division of Hematology and Hemostaseology, MUW, further solidifying his leadership in hematological research.

🔬 Research and Innovation

Dr. Hubmann’s research has made groundbreaking strides in NOTCH signaling and its implications in cancer. His work elucidates the central role of NOTCH2 signaling in CLL leukemogenesis, uncovering vital mechanisms of disease progression. He has identified GLIOTOXIN as a potent therapeutic NOTCH2/CSL transactivation inhibitor, presenting it as a promising alternative to conventional γ-secretase inhibitors. Furthermore, he discovered a tumor-suppressor role for NOTCH3 signaling in CLL, revealing its therapeutic potential. Dr. Hubmann’s studies have highlighted the recurring NOTCH2ΔNRR gain-of-function (GOF) mRNA deletions as potentially disease-defining genetic lesions in CLL. His innovative research also explores somatic recombination involving ancient and recent NOTCH2 gene variants, addressing hereditary, geographic, and gender-based variations.

🧪 Patents and Innovations

Dr. Hubmann’s contributions to translational medicine are protected by several patents. These include Gliotoxin for the treatment of NOTCH2-associated malignancies (WO/2006/135949; US Patent No 7,981,878) and NOTCH21A01/1a4-RFLP as a leukemia/tumor predisposition detection tool (MUW Tech-ID: 835.19). His patented innovations underscore his role in translating basic research into clinical applications.

💡 Technical Expertise

Dr. Hubmann possesses advanced technical skills pivotal to hematology and oncology research. His expertise includes gene expression and silencing techniques such as retroviral vectors and siRNA-mediated gene silencing. He is proficient in molecular analysis, including RT-PCR, Northern & Western blotting, and RNA-seq sequence analysis. His work extends to drug screening models, xenograft mouse models, and developing diagnostic tools for personalized medicine. His ability to blend bioinformatics with preclinical studies further enhances his contributions to the field.

💵 Funding and Grants

Over his career, Dr. Hubmann has secured significant funding for his research. Notable grants include FWF P15100 (2001) for studying the Regulation and Function of NOTCH2 in CLL, and ÖNB Jubiläumsfonds (2002, 2004) for exploring NOTCH2 in leukemogenesis. His work on GLIOTOXIN’s therapeutic potential was supported by Initiative Krebsforschung (2013), while his recent studies on NOTCH2ΔNRR deletions were funded by the Fellinger Krebsforschungsfonds (2022). These funding milestones reflect the impact and importance of his research.

🏆 Awards and Recognition

Dr. Hubmann’s outstanding contributions to medical research have earned him numerous accolades. In 1999, he received the Aventis Stiftung Award for his work on fibroblast growth factor in Hairy Cell Leukemia. His innovative findings on interferon-alpha in Hairy Cell Leukemia earned the Erste Bank Preis in 2001. In 2005 and 2010, he was awarded the Sanofi-Aventis Prize for breakthroughs in cancer therapy and PI3-K/Akt/CK2 signaling. Additionally, the Paracelsus Medical University Award (2008) recognized his research on TGF-β in Radon therapy for Ankylosing Spondylitis patients.

🏢 Professional Memberships

Dr. Hubmann is an esteemed member of the Austrian Society for Hematology and Oncology (ÖGHO). He serves as the Vice Coordinator of the Comprehensive Cancer Center Vienna (CCC) Research Cluster, focusing on Microenvironment, Vasculature, and Metastasis, underscoring his leadership in advancing cancer research.

🎓 Teaching and Mentorship

Since 1998, Dr. Hubmann has played a pivotal role in teaching and mentoring young scientists. He leads specialized courses, including Molecular Biology in Hematology-Oncology and Clinical and Experimental Hematology, since 2001. His dedication extends to supervising Ph.D. and diploma students, nurturing the next generation of researchers and clinicians.

Publications Top Noted📚

Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL Cells

Authors: Rainer Hubmann

Journal: Cells

Year: 2020

UGT2B17 modifies drug response in chronic lymphocytic leukaemia

Authors: Rainer Hubmann

Journal: British Journal of Cancer

Year: 2020

Combined approach for characterization and quality assessment of rabbit bone marrow-derived mesenchymal stem cells intended for gene banking

Authors: Rainer Hubmann

Journal: New Biotechnology

Year: 2020

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

Authors: Rainer Hubmann

Journal: Nature Chemical Biology

Year: 2019

Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells

Authors: Rainer Hubmann

Journal: Biotechnology Progress

Year: 2018

Early Academic Pursuits

Dr. Ihana Aguiar Severo embarked on her academic journey with a strong foundation in Food Science and Technology. She obtained her Bachelor's degree in Food Technology from the Federal University of Santa Maria, Brazil, in 2014. Following this, she pursued a Special Graduate Program for Teacher Training for Professional Education, solidifying her commitment to both research and education.

Her enthusiasm for advancing knowledge in the field led her to pursue a Master's degree in Food Science and Technology at the Federal University of Santa Maria, completing it in 2017. During her master's studies, she delved into the integration of processes for the development of biooxycombustion systems in food industries, showcasing her early interest in sustainable and innovative practices.

Professional Endeavors

Dr. Severo continued her academic journey by earning a Ph.D. in Food Science and Technology from the same institution in 2020. Her doctoral thesis, focused on mass and energy integration in oxycombustion-based microalgae systems in the food industry, demonstrated her commitment to cutting-edge research.

Post her Ph.D., she ventured into the realm of professional research and academia. Dr. Severo's postdoctoral roles include positions at the Sustainable Energy Research and Development Center (NPDEAS) at the Federal University of Paraná, Brazil, and the Center for Advanced Power Systems (CAPS) at the Florida State University in the United States. Her role at CAPS involves significant contributions to research, further establishing her as a key player in the field.

In addition to her research roles, Dr. Severo briefly served as a Professor at the Farroupilha Federal Institute in Brazil, where she imparted knowledge to students in the Technical Course in Agroindustry. This experience showcased her commitment to education and knowledge dissemination.

Contributions and Research Focus On Biotechnology

Dr. Severo has made substantial contributions to the field of microalgal biotechnology, biofuels, bioprocesses for obtaining bioproducts, and effluent treatment. Her prolific research output includes over 70 scientific papers published in specialized journals, book chapters, and conference proceedings. Notably, she holds 5 patents for inventions, including 1 Letters Patent granted.

Her research has explored diverse topics, ranging from microalgae-based processes and products to biofuels, photobioreactors, and process integration. Her expertise extends to areas such as bioremediation and biorefinery, showcasing a multidisciplinary approach to address contemporary challenges in food science and technology.

Impact and Influence

With over 80 scientific documents, including research articles, reviews, books, and conference proceedings, Dr. Severo has significantly influenced the academic landscape. Her edited and authored books, such as "Alginate - Applications and Future Perspectives" and "3rd Generation Biofuels - Disruptive technologies to enable commercial production," underscore her expertise in niche areas.

Legacy and Future Contributions

Dr. Ihana Aguiar Severo's legacy is characterized by her pioneering research in microalgal biotechnology and sustainable energy solutions. Her early academic pursuits, professional endeavors, and significant contributions to the scientific community lay the foundation for a lasting impact. As she continues her postdoctoral research, her future contributions are anticipated to further shape the field, addressing global challenges in food science and technology. Dr. Severo's commitment to innovation and sustainability positions her as a key influencer and contributor to the ongoing advancements in her field.